From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Omega Diagnostics Regulatory Failure a sign of incompetence but does not affect business model: it is still shite & doomed

By Tom Winnifrith | Friday 11 March 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Oh dear. Oh dear. The chaps running Omega Diagnostics (ODX) really are incompetent poltroons.  I wonder how my favourite Saltire waving troll Craig Inglis – who first inspired me to start investigating this POS -  feels about the latest dire news: The UK Health Security Agency rejecting an application for approval of the professional-use VISITECT® COVID-19 Antigen test. Ooops.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 04:33:58